Followers

July 29, 2024

Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug

​The therapy, also known as lecanemab, is approved in the U.S., China, Hong Kong, Israel, Japan and South Korea, and would have been Europe's first drug to treat the neurodegenerative condition rather than its symptoms.

from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/FpnqzIc

No comments:

Post a Comment